We conducted a single-center, prospective clinical trial in which a subcutaneous bortezomib (Bor) regimen [1.6 mg/m<sup>2</sup> per month (BD 1.6 mg/m<sup>2</sup> therapy)] was administered to 22 multiple myeloma patients. All patients had been treated sufficiently with once-monthly subcutaneous Bor injections (BD 1.3 mg/m<sup>2</sup>therapy). Of the 22 patients, 13 had IgG-, 2 had IgA-, and 7 had Bence-Jones protein (BJP)-type multiple myeloma. The observation period for therapeutic effect determination ranged from 84 to 412 days (median: 400 days). Therapeutic effects were investigated in 15 patients during the increase in Bor from 1.3 to 1.6 mg/m<sup>2</sup>, and none achieved complete remission (CR), very good partial remission (VGPR), or partial remission (PR). Given the small number of patients, a significant conclusion must be reached carefully. However, the chance of stronger success with increases in Bor is low for patients who have already undergone long-term 1.3 mg/m<sup>2</sup> Bor treatment. Furthermore, non-hematological toxicity was seen in 12 of 22 patients, so increasing Bor to 1.6 mg/m<sup>2</sup> should be considered carefully. However, the statuses of patients in this study suggest that once-monthly Bor could inhibit disease progression. In future we should investigate low-frequency Bor maintenance therapy.
Previously, we investigated the maximum tolerated dose and dose-limiting toxicity in 3 phase 1 trials involving a total of 123 patients with hematopoietic malignancies and various solid tumors [
Bor therapy, which can offer equivalent therapeutic efficacy while reducing the adverse event frequency, is administered by a subcutaneous injection from an intravenous infusion; non-inferiority studies of subcutaneous Bor injections also exist [
This clinical trial was a single-center, non-randomized, prospective study. The main endpoint was safety and the secondary endpoint was therapeutic efficacy. Twenty-two patients with multiple myeloma who were already receiving BD 1.3 mg/m2 therapy were administered BD 1.6 mg/m2 therapy (
The actual therapeutic approachesare as follows with 28 days comprising one cycle of treatment: Bor 1.6 mg/m2 subcutaneously administered on Day 1 and Dex 20 mg/body on Days 1 and 2 (BD), 13 patients; Bor 1.6 mg/m2 subcutaneously administered on Day 1, Dex 20 mg on Days 1 and 2, Mel 8 mg/body on Days 1-4, and Psl 20 mg/body on Days 1-4 (BMP), 2 patients; Bor 1.6 mg/m2 subcutaneously administered on Day 1, Dex 20 mg on Days 1 and 2, and Tha 50 mg/body on Days 1-28 (BDT50), 13 patients; Bor 1.6 mg/m2 subcutaneously administered on Day 1, Dex 20 mg on Days 1 and 2, and Tha 100 mg/body on Days 1-28 (BDT100), 2 patients; Bor 1.6 mg/m2 subcutaneously administered on Day 1, Dex 20 mg on Days 1 and 2, and Len 10 mg/body on Days 1-28 (BDL10), 1 patient; and Bor 1.6 mg/m2 subcutaneously administered on Day 1, Dex 20 mg on Days 1 and 2, and Len 15 mg/body on Days 1-28 (BDL15), 1 patient.
In all therapeutic approaches, Dex was administered at 20 mg/body on the same day as and the day after Bor administration. Psl, which is used in bone morphogenetic protein (BMP) therapy, was administered at 20 mg/day for roughly 4 days per month; however, appropriate increases or decreases were made at the attending physician’s discretion. Tha was administered every day at 50 or 100 mg/body without a washout period. Len was administered every day for 28 days at 10 or 15 mg/body. The therapeutic effect of increasing the Bor dose was only investigated in IgG- and IgA-type patients, and the evaluation period was the entire period during which the Bor dose was increased. Tha was later added to the regimens of 2 patients who underwent BMP therapy and 7 patients who underwent bortezomib and dexamethasone (BD) therapy; however, because 1 patient in the BMP therapy group and 4 patients in the BD therapy group had IgG- or IgA-type multiple myeloma, they were also subject to therapeutic evaluation.
Meanwhile, the safety of Bor-increase therapy was evaluated throughout the entire period, during which subcutaneous injections of Bor were administered once monthly at a dose of 1.6 mg/m2 to all IgG-, IgA-, and BJP- type patients. The observation period ranged from 28 to 435 days, with a median of 400 days.
The clinical research ethics committee of the institution with which the authors are affiliated approved this study following review (review reference number 431, clinical trial registration number 431). All patients received advance explanations of the purpose of this study and gave their written consent to participate.
No acyclovir, sulfamethoxazole/trimetoprim combinations, or other antibiotics were administered.
Patient no. | Age$/Sex | ISS*/DS¶ | Subtype | Best response before the initial increased bortezomib therapy dose | Disease status at treatment | Preceding bortozomib based treatment more than 3 times per month (months) | Preceding bortozomib based treatment (months) | Treatment | Treatment duration (months) | |
---|---|---|---|---|---|---|---|---|---|---|
1 | 76/F | I/IIIB | IgG | SD | SD | 0 | 32 | BMP Bor 1.6 mg/m2 on Day 1, Mel 8 mg/body on Days 1-4, Dex 20 mg/body on Days 1, 2, Psl 50 mg/body on Days 1-4. | 5 | |
2 | 59/F | I/IA | BJP | ND | ND | 10 | 23 | BMP Bor 1.6 mg/m2 on Day 1, Mel 8 mg/body on Days 1-4, Dex 20 mg/body on Days 1-2, and Psl 20 mg/body on Days 1-4 | 5 | |
3 | 81/F | II/IIIA | IgG | PR | PR | 0 | 15 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 2 | |
4 | 69/F | II/IA | IgG | PR | PR | 0 | 8 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 13# | |
5 | 65/M | II/IIIA | IgG | PR | PR | 3 | 52 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 17# | |
6 | 67/M | I/IIIB | IgG | SD | SD | 2 | 30 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 3 | |
7 | 68/M | II/IIB | IgG | PR | PR | 4 | 45 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 10 | |
8 | 76/M | I/IIA | IgG | PR | PD | 10 | 17 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 4 | |
9 | 87/F | III/IIIA | BJP | CR | CR | 5 | 15 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 7 | |
10 | 64/F | I/IIIA | BJP | VGPR | VGPR | 9 | 19 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 5 | |
11 | 70/F | III/IIIA | IgG | VGPR | VGPR | 0 | 48 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 4 | |
12 | 63/M | I/IIA | IgA | PR | PD | 0 | 9 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 1 | |
13 | 51/M | III/IIIB | BJP | ND | PD | 0 | 41 | BD Bor 1.6 mg/m2 on day 1 and Dex 20 mg/body on Days 1-2 | 5 | |
14 | 76/F | I/IIA | BJP | ND | PD | 1 | 45 | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 5 | |
15 | 44/M | I/IA | IgG | PR | PR | 3 | 27 | BDT100 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/m2 on Days 1-2, and Tha 100 mg/body on Days 1-28 | 9 | |
16 | 87/F | III/IIIB | IgG | PR | PR | 4 | 22 | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 4 | |
17 | 76/F | III/I | IgG | SD | SD | 1 | 33 | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 5 | |
18 | 85/F | II/IIIA | BJP | PR | PR | 0 | 44 | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 1 | |
19 | 60/M | III/IIB | IgG | PR | PR | 2 | 26 | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 17# | |
20 | 90/F | I/IIIA | IgG | PR | PR | 2 | 49 | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 13 # | |
21 | 66/M | I/IIIA | BJP | ND | ND | 0 | 25 | BDT100 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/m2 on Days 1-2, and Tha 100 mg/body on Days 1-28 | 14 # | |
22 | 61/F | I/IIIA | IgA | VGPR | PD | 2 | 24 | BDL10 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/m2 on Days 1-2, and Len 10 mg/body on Days 1-28 | 4 |
ISS, International Staging System; DS, Durie-Salmon Staging System; BJP, Bence-Jones protein multiple myeloma; Bor, bortezomib; Mel, melphalan; Tha, thalidomide; Len, lenalidomide; Dex, dexamethasone; Psl, prednisolone; ND, no data; CR, complete response; VGPR, very good partial respose; PR, partial respose; SD, stable disease; PD, progressive disease; $Age at the initiation of increased bortezomib therapy; *ISS stage at diagnosis; ¶DS stage at diagnosis; # indicates continuation of the initial increased dose bortezomib therapy; BMP: Bor 1.6 mg/m2 on Day 1, Mel 8 mg/body on Days 1-4, Dex 20 mg/body on Days 1-2, and Psl 50 mg/body on Days 1-4; BD: Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2; BDT50: Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28; BDT100: Bor 1.6 mg/m2 on Day 1, Dex 20 mg/m2 on Days 1-2, and Tha 100 mg/body on Days 1-28; BDL10: Bor 1.6 mg/m2 on Day 1, Dex 20 mg/m2 on Days 1-2, and Len 10 mg/body on Days 1-28.
Adverse events were described according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4, published by United States department of health and human services National Institutes of Health and National Cancer Institute 2009.
Judgments were made based on the criteria of the International Myeloma Working Group (IMWG).
The therapeutic efficacy was determined for a total of 15 patients with IgG- and IgA-type multiple myeloma. The observation period ranged from 84 to 421 days, with a median of 400 days. No patients achieved complete remission (CR), very good partial remission (VGPR), or partial remission (PR) with increased Bor doses alone; 10 patients had a stable disease (SD) and 5 had a progressive disease (PD;
Meanwhile, adverse events were evaluated in all patients, including those with BJP-type multiple myeloma. This observation period ranged from 28 to 435 days, with a median of 400 days. Grades 3 and 4 hematological toxicity was observed for a total of 5 times in 3 patients, whereas Grades 3 and 4 non-hematological toxicity was observed for a total of 14 times in 12 of 22 patients (
Although there are only a few existing reports of Bor administration at doses 1.3 mg/m2 or higher [
In actual clinical settings, frequent outpatient clinic visits by elderly patients incur significant costs for medical professionals, patients, and insurers, and future increases in the number of elderly individuals means that discussions regarding costs cannot be avoided. One vial of Bor currently contains 3 mg; however, the amount of wasted Bor is extremely large, given the Japanese physique. In fact, Bor was used a total of 2986 times at our hospital in the 1-year period beginning in July 2013, of which 2549 instances (approximately 85%) involved doses of less than 2.5 mg/body. In the present study, we investigated whether unnecessary waste could be reduced and illness could be improved by increasing the dosage of Bor per injection.
A higher frequency of infectious diseases, including herpes zoster, was observed compared to the past report [
Although our sample size was too small to permit definitive conclusion, unfortunately the chance of greater success was low even when the Bor dosage administered to patients with a stable condition was increased following long-term Bor treatment at 1.3 mg/m2. However, a stable condition may indicate that a once-monthly injection of Bor is effective. Bor therapy at our hospital mostly involves once-monthly injections, with the exception of the induction therapy period, and the median length of the period during which Bor was administered 3 or more times per month was 2 months (0 - 10 months;
Patient No. | Response to the initial increased dose bortezomib therapy | Successive treatments after the initial increased bortezomib treatment | Treatment duration of the second increased dose bortezomib treatment (months) |
---|---|---|---|
1 | PD | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 4 |
2 | * | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 8## |
3 | SD | - | * |
4 | SD | # | * |
5 | SD | # | * |
6 | SD | - | * |
7 | SD | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 2## |
8 | SD | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 9## |
9 | * | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 7## |
10 | * | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 6 |
11 | PD | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 9## |
12 | PD | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 13## |
13 | * | - | * |
14 | * | BDT50 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28 | 3 |
15 | PD | BDL15 Bor 1.6 mg/m2 on Day 1, Dex 20 mg/m2 on Days 1-2, and Len 15 mg/body on Days 1-28 | 3 |
16 | SD | - | * |
17 | PD | - | * |
18 | * | BD Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2 | 1 |
19 | SD | # | * |
20 | PD | # | * |
21 | * | # | * |
22 | PD | - | * |
Bor, bortezomib; Tha, thalidomide; Len, 1 enalidomide; Dex, dexamethasone; Psl, prednisolone; ND, no data; SD, stable disease; PD, progressive disease; * indicates not to be included in the evaluation; - indicates no administration of increased dose bortezomib; BD: Bor 1.6 mg/m2 on Day 1 and Dex 20 mg/body on Days 1-2; BDT50: Bor 1.6 mg/m2 on Day 1, Dex 20 mg/body on Days 1-2, and Tha 50 mg/body on Days 1-28; BDL15: Bor 1.6 mg/m2 on Day 1, Dex 20 mg/m2 on Days 1-2, and Len 15 mg/body on Days 1-2; # indicates continuation of the initial increased dose bortezomib therapy; ## indicates continuation of the second increased dose bortezomib therapy.
Patient No. | Grades 3 and 4 hematological adverse event | Grades 3 and 4 non-hematological adverse event |
---|---|---|
1 | - | herpes zoster infection |
2 | - | - |
3 | - | herpes zoster infection |
4 | - | herpes zoster infection |
5 | - | - |
6 | - | prostatitis, fatigue |
7 | - | - |
8 | - | bacterial pneumonia |
9 | - | fatigue, infection not otherwise specified |
10 | - | - |
11 | - | - |
12 | - | Candida pneumonia |
13 | - | interstitial pneumonia |
14 | neutropenia, twice | neuropathy |
15 | - | - |
16 | - | - |
17 | anemia | nausea |
18 | - | fatigue |
19 | - | - |
20 | - | - |
21 | - | - |
22 | neutropenia, twice | nausea |
- indicates that no Grades 3 and 4 adverse events were observed.
patients’ conditions were stable following low-frequency Bor injection-based therapy was above a median of 24.5 months (7 - 49 months) when counted from the pretreatment phase, suggesting the presence of patients whose conditions could be controlled with once-monthly Bor (Velcade) administration.
The statuses of the subjects in the present study suggest that at least once-monthly Bor injection could inhibit disease progression. In future, it will be necessary to clarify whether any patient’s condition could be stabilized with low-frequency therapy. We also hope for a more detailed investigation of the optimum low-frequency Bor maintenance therapy.
The authors declare that they have no conflicts of interest.